Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguás E et al (2018) Classification and management of adult inflammatory myopathies. Lancet Neurol 17:816–828

Article  PubMed  Google Scholar 

Cobos GA, Femia A, Vleugels RA (2020) Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol 21:339–353

Article  PubMed  Google Scholar 

Sasaki H, Kohsaka H (2018) Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol 28:913–921

Article  CAS  PubMed  Google Scholar 

Yang Z, Lin F, Qin B et al (2015) Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 42:282–291. https://doi.org/10.3899/JRHEUM.140566

Article  PubMed  Google Scholar 

Wang J, Guo G, Chen G et al (2013) Meta-analysis of the association of dermatomyositis and polymyositis with cancer. Br J Dermatol 169:838–847. https://doi.org/10.1111/BJD.12564

Article  CAS  PubMed  Google Scholar 

Buchbinder R, Forbes A, Hall S et al (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. https://doi.org/10.7326/0003-4819-134-12-200106190-00008

Article  PubMed  Google Scholar 

Hsu JL, Liao MF, Chu CC et al (2021) (2021) Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan. Sci Reports 111(11):1–11. https://doi.org/10.1038/s41598-021-83729-5

Article  CAS  Google Scholar 

Shalata W, Zolnoorian J, Meirovitz A, et al (2022) Dermatomyositis Associated with Lung Cancer: A Brief Review of the Current Literature and Retrospective Single Institution Experience. Life (Basel, Switzerland) https://doi.org/10.3390/LIFE13010040

Qiang JK, Kim WB, Baibergenova A, Alhusayen R (2017) Risk of malignancy in dermatomyositis and polymyositis: a systematic review and meta-analysis. J Cutan Med Surg 21:131–136

Article  PubMed  Google Scholar 

Leatham H, Schadt C, Chisolm S et al (2018) Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts. Med (United States). https://doi.org/10.1097/MD.0000000000009639

Article  Google Scholar 

Oronsky B, Ma PC, Morgensztern D, Carter CA (2017) Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia (United States) 19:991–1002

Article  CAS  Google Scholar 

La Rosa S, Uccella S (2021) Classification of neuroendocrine neoplasms: lights and shadows. Rev Endocr Metab Disord 22:527–538

Article  PubMed  Google Scholar 

Lee WY, Kastelik J, Campbell A et al (2012) A case report of dermatomyositis associated with small cell lung cancer. Tumori 98:e158

Article  Google Scholar 

Yu K-L, Ho C-C (2016) Dermatomyositis as the initial presentation of small cell lung cancer: a case report. Thorac Med 31:215–221

Google Scholar 

Takashima R, Takamatsu K, Shinkawa Y et al (2017) Dermatomyositis associated with lung neuroendocrine carcinoma. Intern Med 56:719–724. https://doi.org/10.2169/internalmedicine.56.7768

Article  PubMed  PubMed Central  Google Scholar 

Arnon J, Elia A, Nevo Y, et al (2021) SCLC, Paraneoplastic dermatomyositis, positive transcription intermediary factor 1-γ, and point mutation in the transcription intermediary factor 1-γ coding gene: a case report. JTO Clin Res Reports 2

Kato T, Ito S, Tsuzuki T, et al (2019) Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis. Respirol Case Reports 7

Sheng-Hua Su, Yeh P-F, Te A, Kwang W-K (2014) Small cell lung cancer with paraneoplastic dermatomyositis: a case report. Thorac Med 29:377–383

Google Scholar 

Zhang T, Wu Q, Qin S et al (2019) Lung cancer with dermatomyositis as the initial diagnosis: a case report. Mol Clin Oncol 11:59–62. https://doi.org/10.3892/MCO.2019.1851/DOWNLOAD

Article  PubMed  PubMed Central  Google Scholar 

Ly NTM, Ma N, Ueda-Hayakawa I et al (2021) Clinical and laboratory parameters predicting cancer in dermatomyositis patients with anti-TIF1γ antibodies. J Dermatol Sci 104:177–184. https://doi.org/10.1016/J.JDERMSCI.2021.10.003

Article  CAS  PubMed  Google Scholar 

Mcvera RM, Crawford LJ (2020) TIF1 proteins in genome stability and cancer. Cancers 12:2094. https://doi.org/10.3390/CANCERS12082094

Article  Google Scholar 

De Vooght J, Vulsteke JB, De Haes P et al (2020) Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen. Rheumatology 59:469–477. https://doi.org/10.1093/RHEUMATOLOGY/KEZ572

Article  PubMed  Google Scholar 

Fiorentino DF, Chung LS, Christopher-Stine L et al (2013) Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 65:2954–2962. https://doi.org/10.1002/ART.38093

Article  CAS  PubMed  PubMed Central  Google Scholar 

Best M, Molinari N, Chasset F et al (2019) Use of Anti-transcriptional intermediary factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis. Acta Derm Venereol 99:256–262. https://doi.org/10.2340/00015555-3091

Article  CAS  PubMed  Google Scholar 

McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nat Rev Rheumatol 14:290–302. https://doi.org/10.1038/nrrheum.2018.56

Article  CAS  PubMed  Google Scholar 

Nombel A, Fabien N, Coutant F (2021) Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. https://doi.org/10.3389/FIMMU.2021.773352

Article  PubMed  PubMed Central  Google Scholar 

Gono T, Sato S, Kawaguchi Y et al (2012) Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51:1563–1570. https://doi.org/10.1093/RHEUMATOLOGY/KES102

Article  CAS  PubMed  Google Scholar 

Ceribelli A, Fredi M, Taraborelli M et al (2014) Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 32:891–897

PubMed  Google Scholar 

Labrador-Horrillo M, Martinez MA ngele, Selva-O’Callaghan A, et al (2014) Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res https://doi.org/10.1155/2014/290797

Cao H, Pan M, Kang Y et al (2012) Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken) 64:1602–1610. https://doi.org/10.1002/ACR.21728

Article  PubMed  Google Scholar 

Griniatsos J (2010) Appendiceal neuroendocrine tumors: Recent insights and clinical implications. World J Gastrointest Oncol 2:192

Article  PubMed  PubMed Central  Google Scholar 

Rodríguez P L, Yurgaky S J, Otero RW, Faizal M (2017) Síndromes paraneoplásicos en tumores gastrointestinales. Revisión de tema. Rev Colomb Gastroenterol 32:230–244. https://doi.org/10.22516/25007440.155

dos Anjos CS, Lisita Rosa VD, Godoy ACC, et al (2015) Paraneoplastic dermatomyositis associated with neuroendocrine tumor of an unknown primary site: a case report. Clin Case Reports Rev 1

Hozumi H, Fujisawa T, Nakashima R et al (2016) Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med 121:91–99. https://doi.org/10.1016/j.rmed.2016.10.019

Article  PubMed  Google Scholar 

Xing X, Li A, Li C (2020) Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis. Respir Med 172:106134. https://doi.org/10.1016/j.rmed.2020.106134

Article  PubMed  Google Scholar 

Betteridge Z, McHugh N (2016) Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280:8–23. https://doi.org/10.1111/JOIM.12451

Article  CAS  PubMed  Google Scholar 

Koga T, Fujikawa K, Horai Y et al (2012) The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology 51:1278–1284. https://doi.org/10.1093/RHEUMATOLOGY/KER518

Article  CAS  PubMed  Google Scholar 

Nakashima R, Imura Y, Kobayashi S et al (2010) The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49:433–440. https://doi.org/10.1093/RHEUMATOLOGY/KEP375

Article  CAS  PubMed  Google Scholar 

Hamaguchi Y, Kuwana M, Hoshino K et al (2011) Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147:391–398. https://doi.org/10.1001/ARCHDERMATOL.2011.52

Article  CAS  PubMed  Google Scholar